Dr. Mitchell Gross, M.D.
Medical Oncology (Medical Oncology Physician)
12414 Exposition Blvd
Los Angeles, CA 90064
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 137
Licensed in California since 1996, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Baylor College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A55762 (first issued 1996; current) -
Specialist
CA license A55762 (first issued 1996; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Providence Saint Johns Medical Foundation (281 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 137
- Services billed
- 14,987
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 6,600 | 21 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 371 | 95 |
| Blood test, comprehensive group of blood chemicals | 370 | 95 |
| Lactate dehydrogenase (enzyme) level | 368 | 94 |
| Psa (prostate specific antigen) measurement, total | 358 | 94 |
| Insertion of needle into vein for collection of blood sample | 316 | 95 |
| Testosterone (hormone) level, total | 267 | 88 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 206 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 194 | 87 |
| Established patient office or other outpatient visit, 40-54 minutes | 185 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $131 in total to this clinician.
| Janssen Biotech, Inc. | $131 |
|---|
| Food and Beverage | $131 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $117,287 in research payments for these studies, mostly to the institutions running them.
- A phase 11B study evaluating the safety tolerability pharmacokinetics pharmacodynamics and antitumor activity of PF07220060 as a single agent and as part of combination therapy in participants with advanced solid tumors
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.